Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Title
Intervention Indication Therapeutic Area Year Actions
Etrasimod for treating moderately to severely active ulcerative colitis Etrasimod (ADP334) Ulcerative colitis Gastroenterology 2022 View  |  Download
Etrolizumab for treating moderately to severely active ulcerative colitis in adults Etrolizumab (PRO145223; RG7413; rhuMAb Beta7) Ulcerative colitis Gastroenterology 2020 View  |  Download
Filgotinib for moderately to severely active ulcerative colitis Filgotinib (GLPG-0634; filgotinib maleate) Ulcerative colitis Gastroenterology 2019 View  |  Download
Golimumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years Golimumab Ulcerative colitis Gastroenterology 2023 View  |  Download
Guselkumab for treating ulcerative colitis Guselkumab (Tremfya; CNTO-1959) Ulcerative colitis Gastroenterology 2022 View  |  Download
Mirikizumab for the treatment of moderately to severely active ulcerative colitis Mirikizumab (LY3074828) Ulcerative colitis Gastroenterology 2021 View  |  Download
Ozanimod for moderate to severe ulcerative colitis Ozanimod (RPC1063; Zeposia; ozanimod hydrochloride) Ulcerative colitis Gastroenterology 2020 View  |  Download
Risankizumab for moderate to severe ulcerative colitis Risankizumab (BI 655066; Skyrizi; ABBV 066) Ulcerative colitis Gastroenterology 2022 View  |  Download
Upadacitinib for ulcerative colitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Ulcerative colitis Gastroenterology 2021 View  |  Download
Ustekinumab for Moderately to Severely Active Ulcerative Colitis Ustekinumab (Stelara; CNTO 1275; CNTO-1275) Ulcerative colitis Gastroenterology 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications